References
- BoyleFPendleburySBellDFurther insights into the natural history and management of primary cutaneous neuroendocrine (Merkel cell) carcinomaInt J Radiat Oncol Biol Phys19953123153237836085
- LemosBDStorerBEIyerJGPathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging systemJ Am Acad Dermatol201063575176120646783
- AllenPJBowneWBJaquesDPBrennanMFBusamKCoitDGMerkel cell carcinoma: prognosis and treatment of patients from a single institutionJ Clin Oncol200523102300230915800320
- TaiPTYuEWinquistEChemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 casesJ Clin Oncol200018122493249910856110
- IyerJGBlomADoumaniRResponse rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinomaCancer Med2016592294230127431483
- BhatiaSStorerBEIyerJGAdjuvant radiation therapy and chemotherapy in Merkel cell carcinoma: survival analyses of 6908 cases from the national cancer data baseJ Natl Cancer Inst20161089 pii: djw042
- PoulsenMRischinDWalpoleETrans-Tasman Radiation Oncology GroupHigh-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study – TROG 96:07J Clin Oncol200321234371437614645427
- FooteMVenessMZarateDPoulsenMMerkel cell carcinoma: the prognostic implications of an occult primary in stage IIIB (nodal) diseaseJ Am Acad Dermatol201267339539922030017
- DeneveJLMessinaJLMarzbanSSMerkel cell carcinoma of unknown primary originAnn Surg Oncol20121972360236622271206
- PoulsenMGRischinDPorterIDoes chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin?Int J Radiat Oncol Biol Phys200664111411916125873
- PoulsenMWalpoleEHarveyJWeekly carboplatin reduces toxicity during synchronous chemoradiotherapy for Merkel cell carcinoma of skinInt J Radiat Oncol Biol Phys20087241070107418707820
- HasanSLiuLTripletJLiZMansurDThe role of postoperative radiation and chemoradiation in merkel cell carcinoma: a systematic review of the literatureFront Oncol2013327624294591
- MojicaPSmithDEllenhornJDAdjuvant radiation therapy is associated with improved survival in Merkel cell carcinoma of the skinJ Clin Oncol20072591043104717369567
- LewisKGWeinstockMAWeaverALOtleyCCAdjuvant local irradiation for Merkel cell carcinomaArch Dermatol2006142669370016785371
- ChenMMRomanSASosaJAJudsonBLThe role of adjuvant therapy in the management of head and neck merkel cell carcinoma: an analysis of 4815 patientsJAMA Otolaryngol Head Neck Surg2015141213714125474617
- National Comprehensive Cancer NetworkNCCN guidelines version 1.2017 merkel cell carcinoma2017 Available from: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#mccAccessed May 17, 2017
- PaulsonKGIyerJGBlomASystemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stageJ Invest Dermatol2013133364264623190897
- HeathMJaimesNLemosBClinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU featuresJ Am Acad Dermatol200858337538118280333
- FengHShudaMChangYMoorePSClonal integration of a polyomavirus in human Merkel cell carcinomaScience200831958661096110018202256
- StarrettGJMarcelusCCantalupoPGMerkel cell polyomavirus exhibits dominant control of the tumor genome and transcriptome in virus-associated merkel cell carcinomaMBio201781 pii:e02079-16
- LipsonEJVincentJGLoyoMPD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survivalCancer Immunol Res201311546324416729
- NghiemPTBhatiaSLipsonEJPD-1 Blockade with pembrolizumab in advanced merkel-cell carcinomaN Engl J Med2016374262542255227093365
- KaufmanHLRussellJHamidOAvelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trialLancet Oncol201617101374138527592805
- KaufmanHLRussellJSHamidODurable responses to avelumab (anti-PD-L1) in patients with Merkel cell carcinoma progressed after chemotherapy: 1-year efficacy updatePresented at: AACR Annual MeetingApril 2–5, 2017Washington, DC Abstract CT079
- D’AngeloSPRussellJHasselJCFirst-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): preliminary data from an ongoing studyJ Clin Oncol20173515 Suppl9530